Neurovascularization of the anterior jaw bones revisited using high-resolution magnetic resonance imaging.

R. Jacobs,I. Lambrichts,Xin Liang,W. Martens,N. Mraiwa,P. Adriaensens,J. Gelan

DOI: https://doi.org/10.1016/J.TRIPLEO.2006.11.014

2007-05-01

Abstract:

What problem does this paper attempt to address?

[Giant subgluteal lipoma. Rare cause of sciatica].

G. D’Uva,S. Fiorucci,G. Nasoni

Abstract:
Clozapine-Induced Severe Toxicity: Exploring the Pharmacokinetic Profile of Clozapine and Its Significance in Hemodynamic Instability - A Case Report

Zhu-Xi Yu,Yang Pi,Mei-Kai Chen,Dan-Jiang Dong,Qin Gu

DOI: https://doi.org/10.2147/IMCRJ.S444685

2024-02-08

Abstract:Hemodynamic instability in patients with clozapine intoxication can indirectly reflect the serum concentration of clozapine.We have described a case of a 32-year-old pregnant woman who developed life-threatening clozapine toxicity at 28 weeks of gestation. The levels of clozapine and norclozapine in the serum were high. We initiated hemoperfusion(HP) and other detoxification therapies to remove the drug. The patient had severely dilated peripheral blood vessels, which led to cardiac symptoms such as fatal hypotension and uncontrollable tachycardia, resulting in very high cardiac output and elevated Central venous oxygen saturation (ScvO2). Pharmacological intervention significantly improved the hemodynamics.In light of our observations in the ongoing case, we posit that evaluating hemodynamic parameters before and after blood detoxification could serve as a valuable means to gauge effectiveness and provide guidance for treatment.
Severe clozapine toxicity-The pharmacokinetic profile of clozapine and it’s important role in hemodynamic：case report

Zhu-Xi Yu,Yang PI,Meikai Chen,Danjiang Dong,Qin Gu

DOI: https://doi.org/10.21203/rs.3.rs-2474059/v1

2023-01-01

Abstract:Abstract Background: Hemodynamic instability in patients with clozapine intoxication can indirectly reflect the serum concentration of clozapine. Case presentation: We have described a case of a 32-year-old pregnant woman who developed life-threatening clozapine toxicity at 28 weeks of gestation. The levels of clozapine and norclozapine in the serum were high.We initiated hemoperfusion(HP) and other detoxification therapies to remove the drug. The patient had severely dilated peripheral blood vessels, which led to cardiac symptoms such as fatal hypotension and uncontrollable tachycardia, resulting in very high cardiac output and elevated Central venous oxygen saturation(ScvO2). Pharmacological intervention significantly improved the hemodynamics. Conclusions: Based on our findings in the current case, we hypothesize that hemodynamic monitoring before and after blood detoxification can help assess the efficacy and guide treatment.
Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine

Kohei Kitagawa,Shusuke Uekusa,Yuki Hanai,Itsuki Kimura,Masaru Tsukahara,Azusa Kagawa,Kenji Sasaoka,Yui Sakishiro,Ayaka Miyake,Yuki Watanabe,Daiki Baba,Masafumi Kodama,Yoshiki Kishi,Norihito Yamada,Takashi Yoshio,Kazuhiro Matsuo

DOI: https://doi.org/10.1016/j.ajp.2024.104047

IF: 13.89

2024-04-11

Asian Journal of Psychiatry

Abstract:Psychopharmacotherapy for patients with schizophrenia in Japan has a long history of polypharmacy, which is rare worldwide but remains a critical problem. One reason for this is that clozapine was not available in Japan until 2009. We aimed to investigate the changes in psychopharmacotherapy in patients with schizophrenia over 12 years pre- and post-introduction of clozapine to clarify how psychopharmacotherapy for patients with schizophrenia has changed with the introduction of clozapine. We retrospectively collected data from the medical records of inpatients diagnosed with schizophrenia at the Okayama Psychiatric Medical Center. Chlorpromazine equivalent (CP-eq) decreased from 1276.6 mg/day in 2009 to 613.9 mg/day in 2020. The prescribed daily dose/defined daily dose (PDD/DDD) decreased from 3.0 in 2009 to 1.2 in 2020. The monotherapy rate increased from 24.4% in 2009 to 74.6% in 2020. Our institution began using clozapine in 2010, and the prescription rate for clozapine increased to 37.3% in 2020. The prescription rate for more than three antipsychotics decreased from 27.8% in 2009 to 0.8% in 2020. The increase in clozapine prescription has contributed to an increased rate of antipsychotic monotherapy and a decreased rate of polypharmacy, promoting the optimization of schizophrenia medication. Clozapine therapy should be further promoted in Japan to reduce treatment-resistant schizophrenia due to polypharmacy as much as possible.

psychiatry
Metastatic choriocarcinoma during normal pregnancy presenting as thyroid tumor

A. Eriksson,C. Gezelius

DOI: https://doi.org/10.1007/BF02134008

Archives of Gynecology

Abstract:
Pharmacokinetics of Brexpiprazole, Quetiapine, Risperidone, and Its Active Metabolite Paliperidone in a Postpartum Woman and Her Baby

Toru Konishi,Yumi Kitahiro,Naoko Fujiwara,Kazuhiro Yamamoto,Mari Hashimoto,Takahiro Ito,Kotaro Itohara,Kazumichi Fujioka,Hitomi Imafuku,Ikuo Otsuka,Tomohiro Omura,Ikuko Yano

DOI: https://doi.org/10.1097/ftd.0000000000001197

2024-04-04

Therapeutic Drug Monitoring

Abstract:Background: Brexpiprazole is a second-generation antipsychotic approved in Japan in 2018; however, information on placental passage and breast milk transfer remains limited. In this report, the patient, a 30-year-old pregnant woman with schizophrenia, was medicated with brexpiprazole, risperidone, and quetiapine. Methods: The study used high-performance liquid chromatography–tandem mass spectrometry to determine the concentrations of brexpiprazole, quetiapine, risperidone, and its active metabolite (paliperidone) in maternal and neonatal plasma, cord venous plasma, and breast milk. Maternal plasma samples were obtained approximately 2 and 8 hours after the last administration of antipsychotics on the day of delivery and at the estimated drugs' trough time on days 1, 3, and 5 after delivery. Results: The maternal plasma concentrations of brexpiprazole, quetiapine, and paliperidone increased by approximately 3.5-fold on the fifth day compared with those on the day of delivery, whereas the risperidone concentration remained almost constant. Moreover, the neonatal plasma concentrations of the 4 drugs immediately after birth were indistinguishable from the umbilical cord concentrations and gradually decreased, except for risperidone. Relative infant doses of these compounds were below 1.1%. Conclusions: Pregnancy status notably alters the pharmacokinetic properties of antipsychotics. Therefore, close and careful monitoring of clinical symptoms should be considered during pregnancy and after delivery. Although brexpiprazole is transferred to neonates through the placenta, breastfeeding is still possible because the relative infant dose value of this drug was much less than 10%.

pharmacology & pharmacy,medical laboratory technology,toxicology
Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report

Asiel Yair Adan Sanchez,Jessica J Foster,Carla M Plymen,Sukhi Shergill

DOI: https://doi.org/10.1192/bjpo.bp.116.003723

2016-12-14

BJPsych Open

Abstract:Background: There is currently limited experience in the initiation and maintenance of clozapine for treatment-resistant psychosis in adults with established structural heart disease. These complex patients require close supervision and liaison between colleagues. Here we present the successful experience of treating one such patient within our service and describe a monitoring plan to ensure that these treatments can be provided both safely and effectively. Case presentation: A 36-year-old man with treatment-resistant schizophrenia and known hypertrophic cardiomyopathy (HCM) was admitted to a specialist unit for a trial of clozapine. His psychiatric illness was characterised by multimodal hallucinations and delusions combined with low mood and poor motivation. The diagnosis of HCM was made 3 years previously following a routine electrocardiogram (ECG), and he had remained asymptomatic throughout this time; there were concerns about the risk of initiating clozapine given his pre-existing cardiac condition. Baseline investigations were performed as per local guidelines prior to commencing clozapine; these were within normal limits other than a mildly raised troponin level of 54 ng/L (normal <16 ng/L), which was attributed to the HCM. In addition, baseline transthoracic echocardiography (TTE) was performed which showed no change in the structural heart disease in comparison with previous TTEs. Clozapine was started at 12.5 mg daily and up-titrated to 150 mg twice daily over 14 days as per our institute's guidelines. The patient was monitored with regular testing of troponins, inflammatory markers and ECG. On day 18, the troponin level increased to 1371 ng/L. Creatine kinase and inflammatory markers remained stable. No changes in ECG or TTE were noted and the patient remained clinically asymptomatic. Cardiology opinion was sought and reported that the finding of an isolated elevated troponin was likely to reflect a 'troponin leak' in the context of increased cardiac muscle mass associated with HCM. In the absence of any clinical compromise, it was not felt to be of concern. Clozapine was continued with good effect on mental state. Troponin levels gradually reduced and the patient remained well. Conclusions: While multiple cases of clozapine-induced cardiotoxicity have been reported in the literature, its implications for pre-existing structural disease are unclear. This case report suggests that clozapine can be safely introduced in pre-existing HCM, explores strategies for monitoring and highlights the importance of liaising with experienced cardiologists. Declaration of interest: None. Copyright and usage: © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license.
Antipsychotic Use in Early Pregnancy and the Risk of Maternal and Neonatal Complications

Hsuan-Yu Lin,Fang-Ju Lin,I-Te Wang,Chung-Hsuen Wu,Aaron J. Katz

DOI: https://doi.org/10.1016/j.mayocp.2022.04.006

IF: 11.104

2022-11-01

Mayo Clinic Proceedings

Abstract:ObjectiveTo assess the association between antipsychotic use in early pregnancy and the risk of maternal and neonatal metabolic complications.MethodsWe conducted a population-based retrospective cohort study (January 1, 2010, to December 31, 2016) using the Health and Welfare Database in Taiwan. Pregnant women (18 to 49 years of age) were grouped as antipsychotic users (ie, received oral antipsychotic monotherapy during the first 20 weeks of pregnancy) and nonusers. Antipsychotic users were further categorized into first-generation antipsychotic and second-generation antipsychotic users. Propensity score methods, including matching and inverse probability of treatment weighting, were used to balance covariates. Conditional logistic regression and Cox proportional hazards models were used to compare risks of maternal (gestational diabetes mellitus, preterm birth) and neonatal (low birth weight [LBW], macrosomia) outcomes.ResultsAntipsychotic users had a notably higher risk of preterm birth compared with nonusers (adjusted HR, 1.29; 95% CI, 1.04 to 1.60), but the risk of gestational diabetes mellitus (HR, 1.21; 95% CI, 0.94 to 1.56), LBW (odds ratio [OR], 1.07; 95% CI, 0.84 to 1.37), and macrosomia (OR, 1.36; 95% CI, 0.63 to 2.92) did not differ between the two groups. Among women who received antipsychotics, the odds of LBW were significantly higher in second-generation antipsychotic users compared with first-generation antipsychotic users (adjusted OR, 1.32; 95% CI, 1.04 to 1.68).ConclusionThis study found that using antipsychotics in early pregnancy did not result in a greater risk of metabolic complications both for mothers and newborns. For women requiring treatment with antipsychotics during pregnancy, they should be monitored for the risk of preterm birth and low infant birth weight.

medicine, general & internal
Analysis of the Susceptibility to COVID-19 in Pregnancy and Recommendations on Potential Drug Screening.

Xiaoxuan Zhao,Yuepeng Jiang,Yang Zhao,Hongyan Xi,Chang Liu,Fan Qu,Xiaoling Feng

DOI: https://doi.org/10.1007/s10096-020-03897-6

2020-01-01

Abstract:To analyze the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19, so as to provide evidence for drug selection in clinic. By reviewing the existing literature, this paper analyzes the susceptibility of pregnant women to virus, especially to SARS-CoV-2, from the aspects of anatomical, reproductive endocrine and immune changes during pregnancy and screens effective and fetal-safe treatments from the existing drugs. The anatomical structure of the respiratory system is changed during pregnancy, and the virus transmitted by droplets and aerosols is more easily inhaled by pregnant women and is difficult to remove. Furthermore, the prognosis is worse after infection when compared with non-pregnancy women. And changes in reproductive hormones and immune systems during pregnancy collectively make them more susceptible to certain infections. More importantly, angiotensin-converting enzyme (ACE)-2, the SARS-CoV-2 receptor, has been proven highly increased during pregnancy, which may contribute to the susceptibility to SARS-CoV-2. When it comes to treatment, specific drugs for COVID-19 have not been found at present, and taking old drugs for new use in treating COVID-19 has become an emergency method for the pandemic. Particularly, drugs that show superior maternal and fetal safety are worthy of consideration for pregnant women with COVID-19, such as chloroquine, metformin, statins, lobinavir/ritonavir, glycyrrhizic acid, and nanoparticle-mediated drug delivery (NMDD), etc. Pregnant women are susceptible to COVID-19, and special attention should be paid to the selection of drugs that are both effective for maternal diseases and friendly to the fetus. However, there are still many deficiencies in the study of drug safety during pregnancy, and broad-spectrum, effective and fetal-safe drugs for pregnant women need to be developed so as to cope with more infectious diseases in the future.
Association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage

Tomofumi Ishikawa,Takamasa Sakai,Noriyuki Iwama,Ryo Obara,Kei Morishita,Motohiko Adomi,Aoi Noda,Mami Ishikuro,Saya Kikuchi,Natsuko Kobayashi,Hiroaki Tomita,Masatoshi Saito,Hidekazu Nishigori,Shinichi Kuriyama,Nariyasu Mano,Taku Obara

DOI: https://doi.org/10.1111/acps.13755

Abstract:Objective: To evaluate the association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage. Material and methods: This nested case-control study used a large Japanese administrative database. Pregnancy onset and outcomes were estimated using previously reported algorithms, classifying cases as women becoming pregnant between 2013 and 2022 and ending in a miscarriage. Controls were randomly selected from the entire pregnancy cohort by risk-set sampling with replacement and were individually matched to the cases (3:1). The association between exposure to atypical antipsychotics and risk of miscarriage was assessed using conditional logistic regression adjusted for confounders. The association between benzodiazepine exposure and the risk of miscarriage was assessed as a positive control. Results: In the cohort, 44,118 patients were matched with 132,317 controls. The mean ages (standard deviations) of the case and control groups were 33.3 (5.7) and 33.2 (5.5) years, respectively. The prevalence of atypical antipsychotics was 0.5% in both groups. Aripiprazole is an individual antipsychotic with the highest prescription prevalence. The adjusted odds ratios (aOR) for miscarriage were 0.966 (95% confidence interval [CI], 0.796-1.173) for atypical antipsychotics and 0.998 (0.784-1.269) for aripiprazole. A higher aOR (1.431, 95% CI 1.303-1.573) suggested an association with benzodiazepines. A sensitivity analysis that limited the population to women diagnosed with schizophrenia alone did not suggest an association between atypical antipsychotics and the risk of miscarriage. Conclusions: The results of this study do not suggest an association between exposure to atypical antipsychotics during pregnancy and the risk of miscarriage.
Adverse perinatal pregnancy outcomes in women with schizophrenia: A systematic review and meta-analysis

Wen Tang,Li-Juan Zhou,Wan-Qing Zhang,Yi-Jie Jia,Fei-Hong Hu,Hong-Lin Chen

DOI: https://doi.org/10.1016/j.schres.2023.11.001

IF: 4.662

2023-11-18

Schizophrenia Research

Abstract:Introduction Schizophrenia is a severe mental illness that affects a significant proportion of the global population, particularly those of childbearing age. Several studies have attempted to find an association between schizophrenia and obstetric complications, with varying results. Objective The primary objective of this systematic review and meta-analyses was to summarize the relationship between maternal schizophrenia and perinatal pregnancy outcomes. Data sources PubMed, Web of Science and Ovid EMBASE were searched from January 2001 to September 2022 using keywords related to pregnancy, women, schizophrenia. Study selection A total of 23 independent studies across 21,253 individuals with schizophrenia were identified and included in the analysis. Data extraction The following data were extracted: author, year of publication, country/continent of data collection, study design, demographic characteristics, diagnoses criteria, related complications. Data were analyzed using random-effects pairwise meta-analysis and were reported as prevalence and odd ratios (OR). Statistical heterogeneity was quantified with the I 2 statistic. Results The prevalence of adverse perinatal pregnancy outcomes was represented in descending order: cesarean section (26.0 %); labor induction (24.0 %); small for gestational age (10.5 %); gestational diabetes mellitus (9.2 %); preterm birth (9.1 %); low birth weight (7.8 %); preterm rupture of membranes (6.1 %); 1-Minute Apgar Score < 7 (5.6 %); large for gestational age (5.5 %); birth defect (5.4 %); antepartum hemorrhage (4.4 %);preeclampsia/eclampsia (4.8 %); postpartum hemorrhage (3.9 %); 5-Minute Apgar Score < 7 (3.6 %); gestational hypertension (3.3 %); placental abruption (1.0 %); placenta previa (0.6 %); thromboembolic disease (0.4 %); neonatal mortality (0.3 %) (P ≤ 0.05). There was a higher risk of adverse outcomes including gestational diabetes mellitus, preeclampsia/eclampsia, placental abruption, thromboembolic disease, preterm birth, birth defect, 1-Minute Apgar score < 7, small for gestational age, low birth weight and neonatal mortality compared with non-schizophrenia population (P ≤ 0.05). Conclusions Women with schizophrenia are at higher risk of adverse perinatal pregnancy outcomes. It is imperative that research efforts continue to focus on the reproductive safety of women with schizophrenia during their childbearing years.

psychiatry
Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan

Sayumi Takahashi,Yoichi Kakuta,Taku Obara,Tomofumi Ishikawa,Hiroshi Nagai,Yusuke Shimoyama,Takeo Naito,Rintaro Moroi,Hisashi Shiga,Nariyasu Mano,Yoshitaka Kinouchi,Atsushi Masamune

DOI: https://doi.org/10.1111/jgh.16549

2024-03-29

Journal of Gastroenterology and Hepatology

Abstract:Background and Aim Inflammatory bowel disease (IBD) frequently affects younger patients and poses various challenges concerning pregnancy and childbirth. Maintaining good disease control throughout pregnancy is crucial, but expectant and pregnant patients may worry about the fetal impact of medications, leading to treatment discontinuation due to uncertainty about this issue. This study investigated the real‐world drug‐prescribing practices for pregnant patients with IBD in Japan and their potential connection to major congenital malformations (MCMs). Methods Overall, 277 female IBD patients who gave birth between 2010 and 2019 were selected from the JMDC claims database. The prescribing patterns of IBD medications and MCMs in the patients' offspring were analyzed. Results Among pregnant IBD patients, 74.4% received at least one medication from 90 days before pregnancy to 90 days after delivery. Trends in medication prescriptions during pregnancy in 2010–2019 revealed consistent use of oral 5‐ASA, variable use of topical medications, a decrease in systemic steroids, and an increase in biologics. The prevalence of MCMs in children born to IBD‐affected mothers did not differ significantly between those who did and did not receive IBD medications (8.6% vs 6.8%). Although circulatory system MCMs were slightly more common in the IBD medication group (4.9% vs 1.4%), this difference was not significant. Logistic regression analysis did not reveal an association between MCM risk and first‐trimester use of IBD medications, including corticosteroids and biologics. Conclusions This study provides insights into medication patterns in pregnant IBD patients and suggests no increased risk of MCMs associated with first‐trimester IBD medication use.

gastroenterology & hepatology
The Three Last Years of Manuel II Palaeologus’ Reign Between Two Stroke Attacks: Aphasia or Not?

D. Vassilopoulos,E. Poulakou‐Rebelakou,John V. Palaeologus

DOI: https://doi.org/10.1080/0964704X.2010.516683

2011-10-01

Journal of the History of the Neurosciences

Abstract:The authors attempt to solve the enigma about the possible aphasia of the Byzantine Emperor Manuel II Palaeologus (1391–1425) in the 3-year period between his first and his second and fatal stroke. The texts of historians and chroniclers reveal that Manuel remained semi-paralyzed at bed and his motor disability alienated him from the state affairs and condemned him to isolation from all embassies and contact with others, except his family. Only the funeral oration of the Bishop Bessarion raises the suspicion of a speechless emperor. All testimonies referring to this infirmity are examined.
Induction of Labour: A Comparison of Intranasal and Transbuccal Administration of Oxytocin

S. Sjöstedt

DOI: https://doi.org/10.3109/00016346909157238

1969-01-01

Abstract:
Effect of Maternal Antidepressant Use During the Pre-pregnancy/Early Pregnancy Period on Congenital Heart Disease: A Prospective Cohort Study in Central China

Mengting Sun,Senmao Zhang,Yihuan Li,Letao Chen,Jingyi Diao,Jinqi Li,Jianhui Wei,Xinli Song,Yiping Liu,Jing Shu,Tingting Wang,Peng Huang,Jiabi Qin

DOI: https://doi.org/10.3389/fcvm.2022.916882

IF: 3.6

2022-07-05

Frontiers in Cardiovascular Medicine

Abstract:Background: With the increase in maternal antidepressant prescribing before/during pregnancy, concerns about the safety of antidepressants have come into focus. The purpose of this study was to explore the association between maternal antidepressant use before pregnancy/in early pregnancy and the risk of congenital heart disease (CHD) in children, and to provide a scientific basis for clinical safety of antidepressant use. Methods: The prospective cohort study ultimately included 34,104 singleton pregnancies. Modified Poisson regression model with robust error variances was used to evaluate RRs and 95% confidence intervals (CIs) for the risk of CHD in offspring exposed to maternal antidepressant in the 3 months before pregnancy and early pregnancy. In addition, sensitivity analysis was further performed to explore the robustness of the results. Results: In this study, the maternal antidepressant exposure rate was 2.83% in the 3 months before pregnancy, 2.42% in early pregnancy, and the incidence of CHD was 8.973 per 1,000 live births. We found that maternal antidepressant use in the 3 months before pregnancy and early pregnancy were all associated with an increased risk of CHD, ~2.54 times and 2.87 times, respectively, of non-use of antidepressants after adjusting for potential confounders. This association was also found in CHD specific phenotypic analysis. Of these, offspring whose mothers were exposed to antidepressants in the 3 months before pregnancy had the highest risk of transposition of the great arteries (aOR = 5.50, 95% CI: 1.91–15.88). The offspring of mothers exposed to antidepressants in early pregnancy had the highest risk of developing ventricular septal defect (aOR = 4.80, 95% CI: 2.50–9.24). Sensitivity analysis verified the stability of the results. Conclusions: Maternal antidepressant use in the 3 months before pregnancy and early pregnancy were all associated with an increased risk of CHD in their offspring. In order to reduce the risk of teratogenesis, we recommend that pregnant women prepare for pregnancy after their condition improves or receive the minimum effective dose of medication.

cardiac & cardiovascular systems
Persistence of parvovirus B19 in synovial fluid and bone marrow.

S. Nikkari,A. Roivainen,P. Hannonen,T. Möttönen,R. Luukkainen,T. Yli-Jama,P. Toivanen

DOI: https://doi.org/10.1136/ard.54.7.597

IF: 27.973

1995-07-01

Annals of the Rheumatic Diseases

Abstract:OBJECTIVES--To determine whether parvovirus B19 (B19) persists in rheumatoid arthritis (RA). METHODS--Polymerase chain reaction (PCR) was used to detect parvovirus B19 genome in the synovial fluid cells or peripheral blood mononuclear cells from 61 patients with early RA; bone marrow from one patient was also studied. The synovium or synovial fluid cells from 28 patients with advanced RA, and synovial fluid cell samples from 18 patients with reactive arthritis (as controls) were studied. Two separate sets of primers and probe were used. RESULTS--Parvovirus B19 specific gene sequences were detected in two patients with early arthritis fulfilling the criteria for RA. CONCLUSION--Parvovirus B19 does not play a significant role in the aetiopathogenesis of RA. However, a few cases of a disease indistinguishable from RA may be triggered by parvovirus B19 infection.
Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: A retrospective single-center analysis in Japan

Ayako Kitada,Takehiro Nakai,Sho Fukui,Ryo Rokutanda,Masato Okada,Makio Kusaoi,Ken Yamaji,Naoto Tamura

DOI: https://doi.org/10.1177/09612033221148334

IF: 2.858

2023-01-14

Lupus

Abstract:Lupus, Ahead of Print. ObjectiveTacrolimus is one of the drugs that can be used in pregnancies complicated with systemic lupus erythematosus (SLE), but there are still few reports on its pregnancy outcomes. Although tacrolimus has been reported to cause adverse events, such as increased blood pressure, abnormal glucose metabolism, and susceptibility to infection, there have been no studies on the impact of tacrolimus in SLE pregnancies at these points. We performed a retrospective observational study of pregnancies complicated by SLE at St Luke's International Hospital in Tokyo from April 2003 to August 2021.MethodsBasic clinical information on SLE, pregnancy outcomes, disease activity before and after pregnancy, laboratory results, blood pressure, blood glucose levels, treatment regimens, and presence of infection was extracted from electronic medical records. We defined overall adverse pregnancy outcomes (APOs) as follows: (1) fetal death after 10 gestational weeks, (2) preterm delivery, (3) delivery due to hypertensive disorders of pregnancy, preeclampsia, or placental insufficiency, or (4) the diagnosis of small for gestational age infants. We also examined whether there was a statistical difference in APO incidence between patients treated with and without tacrolimus.ResultsPregnancy outcomes were obtained for 48 patients with a total of 60 pregnancies complicated by SLE. In 20 (33.3%) of these pregnancies, the patients took tacrolimus, and 28 (46.7%) of the pregnancies had APOs. APO incidence did not statistically differ between the tacrolimus and non-tacrolimus groups in the multivariate analysis (p = 1.00, adjusted OR 1, 95% CI: 0.23–4.39). Multiple regression analyses indicated that tacrolimus use did not significantly affect systolic blood pressure in the third trimester (B = −2.23, p = .74) or blood glucose levels in the first trimester (B = 10.2, p = .056). Incidence of infections did not significantly differ between patients treated with and without tacrolimus in the univariate analysis (10.8% vs. 21.1%, p = .42).ConclusionTacrolimus did not significantly affect pregnancy outcomes, blood pressure, or glucose levels. Further research is required to confirm its effects in a larger population.

rheumatology
Overdose of angiotensin II receptor blocker in the third trimester of pregnancy: A case report

Ken Takahashi,Ryota Kobayashi,Kazuhiko Morikawa,Miku Maeda,Osamu Samura,Aikou Okamoto

DOI: https://doi.org/10.1111/jog.16003

2024-06-22

Journal of Obstetrics and Gynaecology Research

Abstract:Angiotensin II receptor blockers (ARBs) are contraindicated during pregnancy because of fetal toxicity. All previous reports on adverse fetal outcomes involved women who continued to take low‐dose ARBs for hypertension and were unaware of the adverse effects. Herein, we report the case of a 23‐year‐old pregnant woman in her third trimester who experienced an ARB overdose after an argument with her partner. Pregnancy was complicated by transient oligohydramnios, and fetal magnetic resonance imaging suggested renal failure. Despite these concerns, the newborn had no morphological abnormalities or abnormal neurological findings. Renal impairment improved over time, and the infant grew well. A single overdose of ARBs in the third trimester can lead to fetal renal failure, similar to long‐term low‐dose ARB administration; however, favorable outcomes are possible. An overdose of ARBs may transiently cause renal failure, which may improve. The study findings may inform counseling for women who are unexpectedly exposed to an overdose of ARBs.

obstetrics & gynecology
Association between infertility treatment and hypertensive disorders of pregnancy in the Japan Birth Cohort Consortium: a meta-analysis

Mami Ishikuro,Tomoko Nishimura,Hiroyoshi Iwata,Hirohito Metoki,Taku Obara,Noriyuki Iwama,Keiko Murakami,Md. Shafiur Rahman,Maki Tojo,Sumitaka Kobayashi,Chihiro Miyashita,Keiko Tanaka,Yoshihiro Miyake,Kazue Ishitsuka,Reiko Horikawa,Naho Morisaki,Midori Yamamoto,Kenichi Sakurai,Chisato Mori,Atsushi Shimizu,Fumihiro Sata,Kenji J. Tsuchiya,Reiko Kishi,Shinichi Kuriyama,the Japan Birth Cohort Consortium

DOI: https://doi.org/10.1038/s41371-023-00890-2

2024-01-12

Journal of Human Hypertension

Abstract:Journal of Human Hypertension, Published online: 10 January 2024; doi:10.1038/s41371-023-00890-2 Association between infertility treatment and hypertensive disorders of pregnancy in the Japan Birth Cohort Consortium: a meta-analysis

peripheral vascular disease
Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study

Marie-Coralie Cornet,Yvonne W Wu,Heather Forquer,Lyndsay A Avalos,Achyuth Sriram,Aaron W Scheffler,Thomas B Newman,Michael W Kuzniewicz

DOI: https://doi.org/10.1136/archdischild-2023-326049

2024-04-18

Abstract:Objective: Selective serotonin reuptake inhibitor (SSRI) use is common in pregnancy. It is associated with delayed neonatal adaptation. Most previous studies have not adjusted for the severity of maternal mental health disorders or examined the impact of SSRI type and dosage. We examined whether treatment with SSRIs in late pregnancy (after 20 weeks) is associated with delayed neonatal adaptation independent of maternal depression and anxiety. Design, setting and patients: Retrospective population-based birth cohort of 280 090 term infants born at 15 Kaiser Permanente Northern California hospitals, 2011-2019. Individual-level pharmacy, maternal, pregnancy and neonatal data were obtained from electronic medical records. Exposure: Dispensed maternal SSRI prescription after 20 weeks of pregnancy. Main outcome measures: Delayed neonatal adaptation defined as a 5 min Apgar score ≤5, resuscitation at birth or admission to a neonatal intensive care unit for respiratory support. Secondary outcomes included each individual component of the primary outcome and more severe neonatal outcomes (pulmonary hypertension, hypoxic-ischaemic encephalopathy and seizures). Results: 7573 (2.7%) infants were exposed to SSRIs in late pregnancy. Delayed neonatal adaptation occurred in 11.2% of exposed vs 4.4% of unexposed infants (relative risk 2.52 (95% CI 2.36 to 2.70)). After multivariable adjustment, there was an association between SSRI exposure and delayed neonatal adaptation (adjusted OR 2.14 (95% CI 1.96 to 2.32)). This association was dose dependent. Escitalopram and fluoxetine were associated with the highest risk of delayed neonatal adaptation. Conclusions: Infants exposed to SSRIs have increased risks of delayed adaptation in a type and dose-dependent relationship, pointing toward a causal relationship.

Neurovascularization of the anterior jaw bones revisited using high-resolution magnetic resonance imaging.

[Giant subgluteal lipoma. Rare cause of sciatica].

Clozapine-Induced Severe Toxicity: Exploring the Pharmacokinetic Profile of Clozapine and Its Significance in Hemodynamic Instability - A Case Report

Severe clozapine toxicity-The pharmacokinetic profile of clozapine and it’s important role in hemodynamic：case report

Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine

Metastatic choriocarcinoma during normal pregnancy presenting as thyroid tumor

Pharmacokinetics of Brexpiprazole, Quetiapine, Risperidone, and Its Active Metabolite Paliperidone in a Postpartum Woman and Her Baby

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report

Antipsychotic Use in Early Pregnancy and the Risk of Maternal and Neonatal Complications

Analysis of the Susceptibility to COVID-19 in Pregnancy and Recommendations on Potential Drug Screening.

Association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage

Adverse perinatal pregnancy outcomes in women with schizophrenia: A systematic review and meta-analysis

Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan

The Three Last Years of Manuel II Palaeologus’ Reign Between Two Stroke Attacks: Aphasia or Not?

Induction of Labour: A Comparison of Intranasal and Transbuccal Administration of Oxytocin

Effect of Maternal Antidepressant Use During the Pre-pregnancy/Early Pregnancy Period on Congenital Heart Disease: A Prospective Cohort Study in Central China

Persistence of parvovirus B19 in synovial fluid and bone marrow.

Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: A retrospective single-center analysis in Japan

Overdose of angiotensin II receptor blocker in the third trimester of pregnancy: A case report

Association between infertility treatment and hypertensive disorders of pregnancy in the Japan Birth Cohort Consortium: a meta-analysis

Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study